Cencora delivered a mixed quarter. While EPS beat and guidance was raised, the company cut its full-year revenue guidance significantly due to faster-than-expected biosimilar conversions at a major customer, slower GLP-1 growth, and other mix shifts. Management emphasized that these are low-margin revenue pressures and that operating income growth remains on track, with core US growth of approximately 7%. Full-year EPS guidance raised to $17.65-$17.90, but revenue growth guidance slashed to 4-6% from 7-9%.
Buzzberg readRaised full-year EPS guidance despite revenue headwindsCencora delivered a mixed quarter. While EPS beat and guidance was raised, the company cut its full-year revenue guidance significantly due to faster-than-expected biosimilar conversions at a major customer, slower GLP-1 growth, and other mix shifts. Management emphasized that these are low-margin revenue pressures and that operating income growth remains on track, with core US growth of approximately 7%. Full-year EPS guidance raised to $17.65-$17.90, but revenue growth guidance slashed to 4-6% from 7-9%.Read full analysisCollapse analysis
Cencora delivered a mixed quarter. While EPS beat and guidance was raised, the company cut its full-year revenue guidance significantly due to faster-than-expected biosimilar conversions at a major customer, slower GLP-1 growth, and other mix shifts. Management emphasized that these are low-margin revenue pressures and that operating income growth remains on track, with core US growth of approximately 7%. Full-year EPS guidance raised to $17.65-$17.90, but revenue growth guidance slashed to 4-6% from 7-9%.
Revenue headwinds included $2B from IRA WAC reductions, faster brand-to-biosimilar conversions at a large mail-order customer, and slower GLP-1 growth.
US Healthcare Solutions operating income grew 6%, with core growth ~7% ex the impact of the oncology customer loss and One Oncology acquisition.
Weather and lower COVID-19 vaccine sales each created $10M operating income headwinds in the quarter.
Reported gross margin was 4.24%, reinforcing the quarter's better-than-guided profitability.
03
Buybacks
Resuming share repurchases: $1 billion by year-end
Revenue headwinds included $2B from IRA WAC reductions, faster brand-to-biosimilar conversions at a large mail-order customer, and slower GLP-1 growth.
04
Demand
Faster brand-to-biosimilar conversions at large mail customer
Management mentioned launching AI-supported tools to improve consistency and quality across customer support operations, with plans to embed these capabilities across the enterprise, but did not discuss AI monetization or demand.
Demand
Bookings & conversion
Faster brand-to-biosimilar conversions at large mail customer. Management emphasized resilience, raised EPS guidance, and reaffirmed long-term growth targets despite revenue headwinds.
The speed of brand-to-biosimilar conversions at a large mail-order pharmacy customer was faster than anticipated, meaningfully reducing revenue growth but not operating income.
“The increase in brand conversions is a meaningful contributor to our reduced revenue growth expectations for the fiscal year, but results in higher margins for Sincora overall.”
The speed of brand-to-biosimilar conversions at a large mail-order pharmacy customer was faster than anticipated, meaningfully reducing revenue growth but not operating income. — This suggests PBMs and mail-order pharmacies are insourcing biosimilar distribution faster than expected, which could pressure revenue for wholesale distributors but may not hurt their long-term profits.
… were, first, manufactured list price reductions, which represented a $2 billion revenue headwind in the quarter, and second, the previously disclosed fiscal 2025 loss of an oncology customer and a grocery customer. The third factor, which was not fully contemplated, was the speed of brand conversions for our large mail-order pharmacy customer. These sales are low margin, which concentrates their impact to our revenue line. The increase in brand conversions is a meaningful contributor to our reduced revenue growth expectations for the fiscal year, but results in higher margins for Sincora overall. Moving now to operating income, U.S. Healthcare Solutions segment operating income increased 6% to $998 million. the quarter we saw good trends across much of our business however there were a few items that impacted our growth first we have not yet lapped the loss of an oncology customer that began to hit our numbers in july 2025 due to its acquisition this headwind was larger than the contribution we recognized from our february 2026 acquisition of one oncology second Many physician offices had lower volumes due to missed patient appointments as a result of inclement weather across …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.